Akèy › Tit travay › Principal Scientist
Principal Scientist: Salè H-1B
310 aplikasyon kondisyon travay te itilize tit travay Principal Scientist. Salè baz medyàn ofri $140,968; mwatye mitan $116,000–$161,585.
Demann (LCA)310
Salè medyan ofri$140,968
Mwatye salè yo$116,000–$161,585
10yèm–90yèm pousantaj$99,616–$176,320
Avoka imigrasyon, rekritè oswa anplwayè? Mete sèvis ou an tèt paj sa a — $99 pou 30 jou →
Anplwayè yo
| Anplwayè | LCA | Salè medyan |
|---|
| Regeneron Pharmaceuticals, Inc. | 42 | $159,918 |
| Bristol-Myers Squibb Company | 24 | $149,456 |
| Pfizer Inc. | 13 | $105,000 |
| Intellia Therapeutics | 7 | $162,750 |
| Eli Lilly and Company | 7 | $119,110 |
| GlaxoSmithKline LLC | 7 | $97,500 |
| Amgen Inc. | 7 | $161,000 |
| Zoetis, Inc. | 6 | $124,692 |
| Sanofi US Services Inc. | 6 | $136,406 |
| Novartis Institutes for BioMedical Research, Inc. | 5 | $116,355 |
| Genentech, Inc. | 5 | $143,200 |
| TCG GreenChem, Inc | 5 | $115,000 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 5 | $155,000 |
| Calder Biosciences Inc. | 5 | $115,000 |
| Janssen Research & Development, LLC | 5 | $165,500 |
| American Cancer Society, Inc. | 4 | $102,804 |
| Medtronic, Inc. | 4 | $127,358 |
| Roche Molecular Systems, Inc. | 4 | $114,400 |
| Riconpharma, LLC | 4 | $108,800 |
| The Children's Hospital of Philadelphia | 3 | $88,046 |
| Stira Pharmaceuticals LLC | 3 | $105,000 |
| ELC Beauty LLC | 3 | $126,250 |
| Honda Research Institute USA, Inc. | 3 | $233,784 |
| Cytiva US LLC | 3 | $130,543 |
| Adare Pharmaceuticals Inc. | 2 | $119,000 |
| Waters Technologies Corporation | 2 | $126,940 |
| PPD Development, L.P. | 2 | $103,555 |
| Repertoire Immune Medicines, Inc. | 2 | $156,567 |
| Alamar Biosciences, Inc. | 2 | $215,930 |
| Alnylam US, Inc. | 2 | $169,500 |
| Hazen and Sawyer, D.P.C. | 2 | $112,902 |
| Nobell Foods, Inc. | 2 | $150,233 |
| Arranta Bio MA LLC | 2 | $154,546 |
| Ionis Pharmaceuticals, Inc. | 2 | $137,280 |
| Epic Pharma LLC | 2 | $130,000 |
| Unnatural Products Inc. | 2 | $172,500 |
| Leica Microsystems Inc. | 2 | $127,000 |
| BrickBio Inc. | 2 | $118,414 |
| ElectraTect, Inc. | 2 | $112,237 |
| JangoBio LLC | 2 | $72,418 |
| Pharmavite LLC | 2 | $124,500 |
| The University of Arizona | 2 | $90,000 |
| Eurofins Professional Scientific Services Mid-Atlantic, LLC. | 2 | $65,880 |
| DeepNephro, Inc. | 2 | $110,000 |
| Pall Corporation | 1 | $118,100 |
| Adobe Inc. | 1 | $215,000 |
| Alvogen, Inc. | 1 | $140,000 |
| Genpharm International LLC | 1 | $148,756 |
| Institute for Protein Innovation Inc. | 1 | $134,826 |
| Teva Pharmaceuticals USA, Inc. | 1 | $145,000 |
| Codiak Biosciences, Inc. | 1 | $175,000 |
| Juno Therapeutics, Inc. | 1 | $159,650 |
| Saint-Gobain Ceramics & Plastics, Inc. | 1 | $125,000 |
| MyoKardia, Inc. | 1 | $151,410 |
| Holobiome, Inc. | 1 | $125,000 |
| Tate & Lyle Solutions USA, LLC | 1 | $114,026 |
| Vor Biopharma Inc. | 1 | $145,000 |
| Actavis Laboratories UT, Inc. | 1 | $127,385 |
| Tergus Pharma, LLC | 1 | $116,000 |
| Massachusetts Eye and Ear Infirmary | 1 | $73,000 |
Pa nivo salè
| Nivo revni | Salè medyan |
|---|
| Nivo I (antre) | $87,157 |
| Nivo II (kalifye) | $136,316 |
| Nivo III (eksperyans) | $130,543 |
| Nivo IV (plen kompetans) | $159,418 |
Depatman Travay la etabli kat nivo salè prevanlan pou chak okipasyon ak zòn, soti nan Nivo I (antre) rive nan Nivo IV (plen kompetans). Anplwayè a chwazi nivo ki koresponn ak kondisyon travay la.
Pa ane fiskal
| Ane fiskal | LCA | Salè medyan |
|---|
| FY2023 | 66 | $133,980 |
| FY2024 | 56 | $140,210 |
| FY2025 | 89 | $135,000 |
| FY2026 | 86 | $155,598 |
Vil yo
- Tarrytown, NY42
- Cambridge, MA28
- South San Francisco, CA14
- Boston, MA7
- New Brunswick, NJ7
- Collegeville, PA7
- Philadelphia, PA6
- Waltham, MA6
- Seattle, WA5
- Devens, MA5
- Ewing, NJ5
- Andover, MA5
- Ridgefield, CT5
- Pensacola, FL4
- San Diego, CA4
- Redwood City, CA4
- Watertown, MA4
- Spring House, PA4
- Los Angeles, CA4
- Denville, NJ4
- Brooklyn, NY3
- Fairfield, NJ3
- Melville, NY3
- San Jose, CA3
- Framingham, MA3
- Thousand Oaks, CA3
- Branchburg, NJ3
- Princeton, NJ3
- New York, NY3
- Pine Brook, NJ2
Salè yo se fen ki pi ba nan salè yo ofri sou chak aplikasyon, konvèti nan yon montan anyèl; estatistik yo itilize sèlman aplikasyon tan plen sètifye. Yon LCA pa yon apwobasyon visa epi yon sèl LCA ka kouvri plizyè pozisyon. Sous: Depatman Travay Etazini, Done Divulgasyon LCA OFLC, ane fiskal 2023–2026 (dènye desizyon Jun 30, 2026).